RAIN study: a protocol for a randomised controlled trial evaluating efficacy, safety and cost-effectiveness of intravenous-to-oral antibiotic switch therapy in neonates with a probable bacterial infection

Fleur M Keij, René F Kornelisse, Nico G Hartwig, Katya Mauff, Marten J Poley, Karel Allegaert, Irwin K M Reiss, Gerdien A Tramper-Stranders, Fleur M Keij, René F Kornelisse, Nico G Hartwig, Katya Mauff, Marten J Poley, Karel Allegaert, Irwin K M Reiss, Gerdien A Tramper-Stranders

Abstract

Introduction: High morbidity and mortality rates of proven bacterial infection are the main reason for substantial use of intravenous antibiotics in neonates during the first week of life. In older children, intravenous-to-oral switch after 48 hours of intravenous therapy has been shown to have many advantages and is nowadays commonly practised. We, therefore, aim to evaluate the effectiveness, safety and cost-effectiveness of an early intravenous-to-oral switch in neonates with a probable bacterial infection.

Methods and analysis: We present a protocol for a multicentre randomised controlled trial assessing the non-inferiority of an early intravenous-to-oral antibiotic switch compared with a full course of intravenous antibiotics in neonates (0-28 days of age) with a probable bacterial infection. Five hundred and fifty patients will be recruited in 17 hospitals in the Netherlands. After 48 hours of intravenous treatment, they will be assigned to either continue with intravenous therapy for another 5 days (control) or switch to amoxicillin/clavulanic acid suspension (intervention). Both groups will be treated for a total of 7 days. The primary outcome will be bacterial (re)infection within 28 days after treatment completion. Secondary outcomes are the pharmacokinetic profile of oral amoxicillin/clavulanic acid, the impact on quality of life, cost-effectiveness, impact on microbiome development and additional yield of molecular techniques in diagnosis of probable bacterial infection.

Ethics and dissemination: This study has been approved by the Medical Ethics Committee of the Erasmus Medical Centre. Results will be presented in peer-reviewed journals and at international conferences.

Trial registration number: NCT03247920.

Keywords: amoxicillin-clavulanic acid; cost-effectiveness; intravenous-to-oral antibiotic switch therapy; microbiome; neonatal infections.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.

Figures

Figure 1
Figure 1
Flow chart of study procedures. 1CRP, C reactive protein; PCT, procalcitonin; RAIN, Reduction of intravenous Antibiotics In Neonates.

References

    1. Cox LM, Yamanishi S, Sohn J, et al. . Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 2014;158:705–21. 10.1016/j.cell.2014.05.052
    1. Gray LE, O’Hely M, Ranganathan S, et al. . The maternal diet, gut bacteria, and bacterial metabolites during pregnancy influence offspring asthma. Front Immunol 2017;8:365 10.3389/fimmu.2017.00365
    1. Johnson CC, Ownby DR. The infant gut bacterial microbiota and risk of pediatric asthma and allergic diseases. Transl Res 2017;179:60–70. 10.1016/j.trsl.2016.06.010
    1. Hyun DY, Hersh AL, Namtu K, et al. . Antimicrobial stewardship in pediatrics: how every pediatrician can be a steward. JAMA Pediatr 2013;167:859–66. 10.1001/jamapediatrics.2013.2241
    1. Fjalstad JW, Stensvold HJ, Bergseng H, et al. . Early-onset Sepsis and Antibiotic Exposure in Term Infants: A Nationwide Population-based Study in Norway. Pediatr Infect Dis J 2016;35:1–6. 10.1097/INF.0000000000000906
    1. Neonatal infection (early onset): antibiotics for prevention and treatment. 2012. (cited 28 Aug 2018).
    1. Tshefu A, Lokangaka A, Ngaima S, et al. . Simplified antibiotic regimens compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with clinical signs of possible serious bacterial infection when referral is not possible: a randomised, open-label, equivalence trial. Lancet 2015;385:1767–76. 10.1016/S0140-6736(14)62284-4
    1. Mir F, Nisar I, Tikmani SS, et al. . Simplified antibiotic regimens for treatment of clinical severe infection in the outpatient setting when referral is not possible for young infants in Pakistan (Simplified Antibiotic Therapy Trial [SATT]): a randomised, open-label, equivalence trial. Lancet Glob Health 2017;5:e177–e185. 10.1016/S2214-109X(16)30335-7
    1. Baqui AH, Saha SK, Ahmed AS, et al. . Safety and efficacy of alternative antibiotic regimens compared with 7 day injectable procaine benzylpenicillin and gentamicin for outpatient treatment of neonates and young infants with clinical signs of severe infection when referral is not possible: a randomised, open-label, equivalence trial. Lancet Glob Health 2015;3:e279–e287. 10.1016/S2214-109X(14)70347-X
    1. Fuchs JB A, Mathur S, Sharland M, et al. . Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update. WHO-Reviews, 2016.
    1. Mir F. Thesis: High dose oral amoxicillin attains pharmacokinetic efficacy endpoints in young infants (0-59 days) with suspected sepsis - a population pharmacokinetic pilot study. EMORY Electronic Theses and Dissertations, 2013.
    1. Autret E, Laugier J, Marimbu J, et al. . Comparison between IV and oral route amoxicillin administration in neonatal bacterial colonization. Arch Fr Pediatr 1988;45:679–82.
    1. Gras-Le Guen C, Boscher C, Godon N, et al. . Therapeutic amoxicillin levels achieved with oral administration in term neonates. Eur J Clin Pharmacol 2007;63:657–62. 10.1007/s00228-007-0307-3
    1. Manzoni P, Esposito S, Gallo E, et al. . Switch therapy in full-term neonates with presumed or proven bacterial infection. J Chemother 2009;21:68–73. 10.1179/joc.2009.21.1.68
    1. Chiesa C, Natale F, Pascone R, et al. . C reactive protein and procalcitonin: reference intervals for preterm and term newborns during the early neonatal period. Clin Chim Acta 2011;412(11-12):1053–9. 10.1016/j.cca.2011.02.020
    1. Chiesa C, Panero A, Rossi N, et al. . Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. Clin Infect Dis 1998;26:664–72. 10.1086/514576
    1. Green PA, Singh KV, Murray BE, et al. . Recurrent group B streptococcal infections in infants: clinical and microbiologic aspects. J Pediatr 1994;125(6 Pt 1):931–8. 10.1016/S0022-3476(05)82012-8
    1. Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ 1992;41:25–32.
    1. Ekelund K, Konradsen HB. Invasive group B streptococcal disease in infants: a 19-year nationwide study. Serotype distribution, incidence and recurrent infection. Epidemiol Infect 2004;132:1083–90. 10.1017/S0950268804002808
    1. Giannoni E, Agyeman PKA, Stocker M, et al. . Neonatal Sepsis of Early Onset, and Hospital-Acquired and Community-Acquired Late Onset: A Prospective Population-Based Cohort Study. J Pediatr 2018;201:106–14. 10.1016/j.jpeds.2018.05.048
    1. de Hoog M, Mouton JW, van den Anker JN. New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med 2005;10:185–94. 10.1016/j.siny.2004.10.004
    1. EUCAST. European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters Version 8.1, 2018.
    1. Nederland Z. Guidelines for economic evaluations of health care: National Health Care Institute, 2016.
    1. Nederland Z. Manual for costing research. Methods and reference prices for economic evaluations in health care: National Health Care Institute, 2015.
    1. Bouwmans C, Krol M, Severens H, et al. . The iMTA productivity cost questionnaire: a standardized instrument for measuring and valuing health-related productivity losses. Value Health 2015;18:753–8. 10.1016/j.jval.2015.05.009
    1. Stocker M, van Herk W, El Helou S, et al. . Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns). Lancet 2017;390:871–81. 10.1016/S0140-6736(17)31444-7

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren